About: Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $8.80 (+1.38%)
XLO NASDAQ Xilio Development Inc
Xilio Development Inc share price
XLO price activity
Last Price
$8.750
Change (24hr)
0.07 USD (0.81%)
Volume
5.13K
Volume (4w avg)
-
Open
$8.44
Day Range
$8.43 - $8.84
Previous Close
$8.68
Last Trade
04 Nov, 4:44 pm GMT+0
Delayed
04 Nov, 4:44 pm GMT+0
XLO price performance
Delayed
04 Nov, 4:44 pm GMT+0
XLO details
XLO Market Signals